Interim Report 2026
Filed with HKEX · Stock code 2186 · · 69 pages · English
Company Overview Corporate Information Financial Highlights Management Discussion and Analysis Other Information Independent Review Report Interim Condensed Consolidated Statement of Profit or Loss Interim Condensed Consolidated Statement of Comprehensive Income Interim Condensed Consolidated Statement of Financial Position Interim Condensed Consolidated Statement of Changes in Equity 40 Interim C
Earlier from Luye Pharma
- Luye Pharma Announces 2026 Interim Results
- Luye Pharma Announces Successful Completion of a U.S. Bridging Clinical Trial of Its Innovative Drug LY03015 (VMAT2 Inhibitor/Sigma-1R...
- Luye Pharma Announces Positive Phase 2 Results of LY03015, a VMAT2 Inhibitor and Sigma-1R Agonist, for Tardive Dyskinesia in China
- Luye Pharma Announces First Subject Enrolled in U.S. PK Bridging Clinical Trial of Its VMAT2 Inhibitor/Sigma-1R Agonist LY03015
- First Subject Enrolled in Phase Ⅱ Clinical Trial of Luye Pharma’s TAAR1/5-HT2CR-targeted Investigational Drug for Treating...
Later from Luye Pharma
All Luye Pharma news releasesFollow Luye Pharma into a list and get an email when it puts out news.
Follow Luye Pharma